Bon Ham Yip

Designation:
Staff scientist
Department:
Hematology
University:
St Jude Childrens Research Hospital
Country:
USA
Journal Associated: Studies on Stem Cells Research and Therapy Biography:

A senior staff scientist has more than 10 years of experience in hematology and stem cell research. My research interest covers in vitro and in vivo functional study of leukemia-causing mutation and development of viral vectors for gene therapy. I have received my PhD from The Institute of Cancer Research, London, UK with a focus on mouse modelling of Mixed Lineage Leukaemia gene amplification. Then, I became a post-doctoral research scientist at the University of Oxford, UK with a focus on functional characterization of splicing factor mutations in MDS. After that I worked as a Gene editing Senior scientist in Adaptimmune Ltd for T-cell immunotherapy. At the moment I am a staff scientist at St Jude Children Research Hospital Vector Development Core specialized in development of viral vector for gene therapy. 

Research Interest: Hematology; leukemia; mouse modelling; gene editing; stem cells; viral vectors; gene therapy

URL: https://www.linkedin.com/in/bonhamyip/

Grants: 2010-2016 funded by Bloodwise UK

Skype ID: oscarbonham@yahoo.com

List of Publications: 

PRR14L mutations are associated with chromosome 22 acquired uniparental disomy, age-related clonal hematopoiesis and myeloid neoplasia.

Chase A, Pellagatti A, Singh S, Score J, Tapper WJ, Lin F, Hoade Y, Bryant C, Trim N, Yip BH, Zoi K, Rasi C, Forsberg LA, Dumanski JP, Boultwood J, Cross NCP.

Leukemia. 2018 Dec 20. doi: 10.1038/s41375-018-0340-5. [Epub ahead of print]

L-leucine increases translation of RPS14 and LARP1 in erythroblasts from del(5q) myelodysplastic syndrome patients.

Bello E, Kerry J, Singh S, Yip BH, Kušec R, Killick S, Raynaud S, Boultwood J, Pellagatti A.

Haematologica. 2018 Nov;103(11):e496-e500. doi: 10.3324/haematol.2018.190447. Epub 2018 Jun 14. No abstract available. 

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.

Yip BH, Steeples V, Repapi E, Armstrong RN, Llorian M, Roy S, Shaw J, Dolatshad H, Taylor S, Verma A, Bartenstein M, Vyas P, Cross NC, Malcovati L, Cazzola M, Hellström-Lindberg E, Ogawa S, Smith CW, Pellagatti A, Boultwood J.

J Clin Invest. 2017 Sep 1;127(9):3557. doi: 10.1172/JCI96202. Epub 2017 Sep 1. No abstract available. 

Amplification of mixed lineage leukemia gene perturbs hematopoiesis and cooperates with partial tandem duplication to induce acute myeloid leukemia.

Yip BH, Tsai CT, Rane JK, Vetharoy W, Anguita E, Dong S, Caligiuri MA, So CWE.

Haematologica. 2017 Aug;102(8):e300-e304. doi: 10.3324/haematol.2016.161406. Epub 2017 May 18. No abstract available. 

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.

Yip BH, Steeples V, Repapi E, Armstrong RN, Llorian M, Roy S, Shaw J, Dolatshad H, Taylor S, Verma A, Bartenstein M, Vyas P, Cross NC, Malcovati L, Cazzola M, Hellström-Lindberg E, Ogawa S, Smith CW, Pellagatti A, Boultwood J.

J Clin Invest. 2017 Jun 1;127(6):2206-2221. doi: 10.1172/JCI91363. Epub 2017 Apr 24. Erratum in: J Clin Invest. 2017 Sep 1;127(9):3557. 

Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.

Dolatshad H, Pellagatti A, Liberante FG, Llorian M, Repapi E, Steeples V, Roy S, Scifo L, Armstrong RN, Shaw J, Yip BH, Killick S, Kušec R, Taylor S, Mills KI, Savage KI, Smith CW, Boultwood J.

Leukemia. 2016 Dec;30(12):2322-2331. doi: 10.1038/leu.2016.149. Epub 2016 May 23.

Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes.

Yip BH, Dolatshad H, Roy S, Pellagatti A, Boultwood J.

Curr Pharm Des. 2016;22(16):2333-44. Review.

ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts.

Valletta S, Dolatshad H, Bartenstein M, Yip BH, Bello E, Gordon S, Yu Y, Shaw J, Roy S, Scifo L, Schuh A, Pellagatti A, Fulga TA, Verma A, Boultwood J.

Oncotarget. 2015 Dec 29;6(42):44061-71. doi: 10.18632/oncotarget.6392.

Application of genome editing technologies to the study and treatment of hematological disease.

Pellagatti A, Dolatshad H, Yip BH, Valletta S, Boultwood J.

Adv Biol Regul. 2016 Jan;60:122-134. doi: 10.1016/j.jbior.2015.09.005. Epub 2015 Sep 26. Review.

Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.

Dolatshad H, Pellagatti A, Fernandez-Mercado M, Yip BH, Malcovati L, Attwood M, Przychodzen B, Sahgal N, Kanapin AA, Lockstone H, Scifo L, Vandenberghe P, Papaemmanuil E, Smith CW, Campbell PJ, Ogawa S, Maciejewski JP, Cazzola M, Savage KI, Boultwood J.

Leukemia. 2015 Aug;29(8):1798. doi: 10.1038/leu.2015.178. No abstract available. 

Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.

Dolatshad H, Pellagatti A, Fernandez-Mercado M, Yip BH, Malcovati L, Attwood M, Przychodzen B, Sahgal N, Kanapin AA, Lockstone H, Scifo L, Vandenberghe P, Papaemmanuil E, Smith CW, Campbell PJ, Ogawa S, Maciejewski JP, Cazzola M, Savage KI, Boultwood J.

Leukemia. 2015 May;29(5):1092-103. doi: 10.1038/leu.2014.331. Epub 2014 Nov 27. Erratum in: Leukemia. 2015 Aug;29(8):1798. Leukemia. 2015 Aug;29(8):1798. 

The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.

Boultwood J, Dolatshad H, Varanasi SS, Yip BH, Pellagatti A.

Adv Biol Regul. 2014 Jan;54:153-61. doi: 10.1016/j.jbior.2013.09.005. Epub 2013 Sep 15. Review.

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.

Caceres G, McGraw K, Yip BH, Pellagatti A, Johnson J, Zhang L, Liu K, Zhang LM, Fulp WJ, Lee JH, Al Ali NH, Basiorka A, Smith LJ, Daugherty FJ, Littleton N, Wells RA, Sokol L, Wei S, Komrokji RS, Boultwood J, List AF.

Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16127-32. doi: 10.1073/pnas.1311055110. Epub 2013 Sep 16.

Mixed lineage leukemia protein in normal and leukemic stem cells.

Yip BH, So CW.

Exp Biol Med (Maywood). 2013 Mar;238(3):315-23. doi: 10.1177/1535370213480717. Review.

Activation of the mTOR signaling pathway by L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts.

Yip BH, Vuppusetty C, Attwood M, Giagounidis A, Germing U, Lamikanra AA, Roberts DJ, Maciejewski JP, Vandenberghe P, Mecucci C, Wainscoat JS, Pellagatti A, Boultwood J.

Leukemia. 2013 Aug;27(8):1760-3. doi: 10.1038/leu.2013.20. Epub 2013 Jan 22. No abstract available. 

Silencing of ASXL1 impairs the granulomonocytic lineage potential of human CD34⁺ progenitor cells.

Davies C, Yip BH, Fernandez-Mercado M, Woll PS, Agirre X, Prosper F, Jacobsen SE, Wainscoat JS, Pellagatti A, Boultwood J.

Br J Haematol. 2013 Mar;160(6):842-50. doi: 10.1111/bjh.12217. Epub 2013 Jan 8.

Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q- syndrome and other ribosomopathies.

Boultwood J, Yip BH, Vuppusetty C, Pellagatti A, Wainscoat JS.

Adv Biol Regul. 2013 Jan;53(1):8-17. doi: 10.1016/j.jbior.2012.09.002. Epub 2012 Sep 13. Review.

Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.

Fernandez-Mercado M, Yip BH, Pellagatti A, Davies C, Larrayoz MJ, Kondo T, Pérez C, Killick S, McDonald EJ, Odero MD, Agirre X, Prósper F, Calasanz MJ, Wainscoat JS, Boultwood J.

PLoS One. 2012;7(8):e42334. doi: 10.1371/journal.pone.0042334. Epub 2012 Aug 9.

Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts.

Yip BH, Pellagatti A, Vuppusetty C, Giagounidis A, Germing U, Lamikanra AA, Roberts DJ, Fernandez-Mercado M, McDonald EJ, Killick S, Wainscoat JS, Boultwood J.

Leukemia. 2012 Sep;26(9):2154-8. doi: 10.1038/leu.2012.82. Epub 2012 Mar 20. No abstract available. 


Global Views

Case Reports

Peertechz Tweets